LRMR

Healthcare Biotechnology

Larimar Therapeutics, Inc.

$2.96

-0.25 -7.83% today

Price History

Not enough data

Key Stats

Market Cap

307.49M

Avg Volume

1.36M

EPS

-$1.99

52W High

$6.42

52W Low

$2.72

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-2.79

P/B Ratio

2.43

EV/EBITDA

-0.88

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(139.6%)

Return on Assets

(71.0%)

Liquidity & Leverage

Current Ratio

4.70

Quick Ratio

4.58

Debt / Equity

0.04

Total Cash

156.27M

Total Debt

4.96M

About

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.